Share this article on:

FDA Fast Track Designation for Myocet for Metastatic Breast Cancer

doi: 10.1097/01.COT.0000368457.66658.a6

The Food and Drug Administration has granted Fast Track status to nonpegylated liposomal doxorubicin (Myocet, made by Sopherion Therapeutics) for first-line therapy of HER2-positive metastatic breast cancer, which has shown reduced cardiotoxicity compared with traditional doxorubicin.

© 2010 Lippincott Williams & Wilkins, Inc.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!